Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NEO 
NeoGenomics Inc (NEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NEO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $9.78
1 Year Target Price $9.78
| 6 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.59% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.13B USD | Price to earnings Ratio - | 1Y Target Price 9.78 |
Price to earnings Ratio - | 1Y Target Price 9.78 | ||
Volume (30-day avg) 14 | Beta 1.54 | 52 Weeks Range 4.72 - 19.11 | Updated Date 08/29/2025 |
52 Weeks Range 4.72 - 19.11 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.1% | Operating Margin (TTM) -15.43% |
Management Effectiveness
Return on Assets (TTM) -3.25% | Return on Equity (TTM) -11.76% |
Valuation
Trailing PE - | Forward PE 222.22 | Enterprise Value 1179455864 | Price to Sales(TTM) 1.65 |
Enterprise Value 1179455864 | Price to Sales(TTM) 1.65 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA -27.92 | Shares Outstanding 129179000 | Shares Floating 119990147 |
Shares Outstanding 129179000 | Shares Floating 119990147 | ||
Percent Insiders 1.29 | Percent Institutions 100.55 |
Upturn AI SWOT
NeoGenomics Inc
Company Overview
History and Background
NeoGenomics, Inc. was founded in 2002. Initially focused on cytogenetics testing, it has grown through acquisitions and organic growth to offer a comprehensive suite of cancer testing services. Key milestones include acquisitions of PathLabs, Clarient, and Genoptix.
Core Business Areas
- Oncology: Provides comprehensive cancer genomic testing services for pathologists, oncologists, academic researchers, and pharmaceutical companies, aiding in diagnosis, prognosis, and treatment decisions.
- Pharma Services: Offers testing and related services to pharmaceutical companies to support drug development and clinical trials.
Leadership and Structure
The leadership team includes Chris Smith (CEO) and Kathryn Stalmack (CFO). The organizational structure is divided into operational units focusing on oncology testing services and pharma services.
Top Products and Market Share
Key Offerings
- Comprehensive Genomic Profiling (CGP): This includes broader molecular profiling testing to assess a patient's genomic landscape. Market share is dynamic, with increased competition in this segment. Competitors include Foundation Medicine (FMI), Caris Life Sciences, and Guardant Health (GH).
- FISH (Fluorescence In Situ Hybridization): A common molecular cytogenetic technique used to detect and localize specific DNA sequences on chromosomes. Competitors include Laboratory Corporation of America (LH), Quest Diagnostics (DGX), and PathGroup.
- IHC (Immunohistochemistry): Involves the process of selectively imaging antigens in cells of a tissue section. Competitors include Laboratory Corporation of America (LH), Quest Diagnostics (DGX), and PathGroup.
Market Dynamics
Industry Overview
The cancer diagnostics market is growing rapidly due to increasing cancer incidence, advancements in genomic technologies, and the rising demand for personalized medicine.
Positioning
NeoGenomics is a leading provider of cancer genomic testing services, particularly for community-based oncologists and pathologists. Competitive advantages include its broad test menu, customer service, and established relationships.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics is expected to reach hundreds of billions of dollars. NeoGenomics is positioned to capture a significant portion of this market through its extensive testing capabilities and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Broad test menu
- Strong customer relationships
- Established infrastructure
- Experienced management team
Weaknesses
- Integration challenges from acquisitions
- High debt load
- Dependence on reimbursement rates
- Competition in CGP market
Opportunities
- Expanding pharma services
- Entering new markets
- Developing new tests
- Strategic partnerships
Threats
- Increased competition
- Changes in reimbursement policies
- Economic downturn
- Regulatory changes
Competitors and Market Share
Key Competitors
- FMI
- LH
- DGX
- GH
- QDEL
Competitive Landscape
NeoGenomics competes on price, test menu breadth, and customer service. Foundation Medicine (FMI) is a strong competitor with advanced technology and large market share. Laboratory Corporation of America (LH) and Quest Diagnostics (DGX) are large diagnostic providers with extensive networks.
Major Acquisitions
Clarient
- Year: 2015
- Acquisition Price (USD millions): 267
- Strategic Rationale: Expanded test menu and market reach in cancer diagnostics.
Genoptix
- Year: 2011
- Acquisition Price (USD millions): 180
- Strategic Rationale: Expanded testing capabilities and geographic presence.
Growth Trajectory and Initiatives
Historical Growth: NeoGenomics has grown both organically and through acquisitions. Historical growth rates are found in SEC filings.
Future Projections: Future growth projections depend on market conditions and the company's execution of its strategy. Analyst estimates should be consulted for accurate predictions.
Recent Initiatives: Recent initiatives focus on expanding pharma services and enhancing its oncology testing menu.
Summary
NeoGenomics is a key player in the cancer diagnostics market with a broad testing menu. The company faces intense competition but benefits from established relationships. Future success relies on effective integration of acquisitions and expanding into pharma services. Weaknesses such as debt load and competition should be monitored, and strength from the leadership should be capitalized on.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Financial News Outlets
Disclaimers:
This information is for informational purposes only and should not be considered investment advice. Financial data is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeoGenomics Inc
Exchange NASDAQ | Headquaters Fort Myers, FL, United States | ||
IPO Launch date 1999-11-02 | CEO & Director Mr. Anthony P. Zook | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 2200 | Website https://www.neogenomics.com |
Full time employees 2200 | Website https://www.neogenomics.com | ||
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.